Drug approvals in 2024

Following is a list of drugs for neurologic conditions that have received approval from the U.S. Food and Drug Administration in 2024.

Alzheimer disease

KISUNLA™ (donanemab-azbt) injection
Approval granted: July 2, 2024
Indication: For the treatment of patients in the mild cognitive impairment or mild dementia stage of Alzheimer disease.
US FDA Press Release
Drug Trials Snapshot
Prescribing Information

Duchenne muscular dystrophy

DUVYZAT™ (givinostat)
Approval granted: March 21, 2024
Indication: For the treatment of Duchenne muscular dystrophy in patients 6 years of age and older
US FDA Press Release
Drug Trials Snapshot
Prescribing Information

Grade 2 astrocytoma or oligodendroglioma

VORANIGO® (vorasidenib) an isocitrate dehydrogenase-1 (IDH1) and isocitrate dehydrogenase-2 (IDH2) inhibitor
Approval granted: August 6, 2024
Indication: For the treatment of adult and pediatric patients 12 years and older with Grade 2 astrocytoma or oligodendroglioma with a susceptible isocitrate dehydrogenase-1 (IDH1) or
isocitrate dehydrogenase-2 (IDH2) mutation following surgery including biopsy, sub-total resection, or gross total resection.
US FDA Press Release
Prescribing Information

Niemann-Pick disease type C

AQNEURSA™ (levacetylleucine)
Approval granted: September 24, 2024
Indication: Treatment of neurologic symptoms associated with Niemann-Pick disease type C in adults and pediatric patients weighing at least 15 kg
US FDA Press Release
Prescribing Information

MIPLYFFA™ (arimoclomol)
Approval granted: September 20, 2024
Indication: For use in combination with miglustat for the treatment of neurologic manifestations of Niemann-Pick disease type C in adult and pediatric patients 2 years of age and older.
US FDA Press Release
Prescribing Information

Relapsed or refractory pediatric low-grade glioma

OJEMDA™ (tovorafenib) a kinase inhibitor
Approval granted: April 23, 2024
Indication: For the treatment of patients 6 months of age and older with relapsed or refractory pediatric low-grade glioma harboring a BRAF fusion or rearrangement or BRAF V600 mutation
US FDA Press Release
Drug Trials Snapshot
Prescribing Information